Muhammad Furqan, Nikhil Mukhi, Byung Moo Lee, Delong Liu
AbstractJAK-STAT (Janus associated kinase-signal transducer and activator of
transcription) pathway plays a critical role in transduction of extracellular
signals from cytokines and growth factors involved in hematopoiesis, immune
regulation, fertility, lactation, growth and embryogenesis. JAK family contains
four cytoplasmic tyrosine kinases, JAK1-3 and Tyk2. Seven STAT proteins have
been identif... hiện toàn bộ
AbstractChimeric antigen receptor T-cell (CAR-T) therapy is the result of
combining genetic engineering-based cancer immunotherapy with adoptive cell
therapy (ACT). CAR-T therapy has been successful in treating various types of
hematological cancers. CARs are receptors made of an extracellular domain, a
membrane-spanning domain, and an intracellular domain. The extracellular domain
of CARs harbors... hiện toàn bộ
Abstract Hepatocellular carcinoma (HCC) is one of the most common malignant
tumors in the world. Currently, surgical resection, liver transplantation, and
local ablation are considered curative therapeutic practices for HCC. The
diagnosis of HCC without pathologic confirmation is achieved by analyzing serum
alpha-fetoprotein (AFP) levels combined with imaging techniques, including
ultrasonography,... hiện toàn bộ
Fuyong Du, Anthony Virtue, Hong Wang, Xiaofeng Yang
Abstract Insulin resistance associated with type 2 diabetes mellitus (T2DM),
obesity, and atherosclerosis is a global health problem. A portfolio of
abnormalities of metabolic and vascular homeostasis accompanies T2DM and
obesity, which are believed to conspire to lead to accelerated atherosclerosis
and premature death. The complexity of metabolic changes in the diseases
presents challenges for a ... hiện toàn bộ
Abstract Background We evaluated organ-specific response rates (OSRRs) to
first-line lenvatinib plus anti-PD-1 antibodies in patients with advanced
hepatocellular carcinoma (HCC). Methods This retrospective analysis included
Chinese patients with unresectable/advanced HCC who received first-line
lenvatinib (8 mg/day) plus ≥3 infusions of anti-PD-1 antibodies between October
2018 and May 2020. Tumo... hiện toàn bộ